A Modular Trial of Androgen Signaling Inhibitor Combinations Testing a Risk-Adapted Strategy in Patients with Metastatic Castration-Resistant Prostate Cancer.

Ana M Aparicio Rebecca S Slack Tidwell Shalini Singh Yadav Jiun-Sheng Chen Miao Zhang JIngjing Liu Shuai Guo Patrick G Pilié Yao Yu Xingzhi Song Haswanth Vundavilli Sonali Jindal Keyi Zhu Paul V Viscuse Justin M Lebenthal Andrew W Hahn Rama Soundararajan Paul Gettys Corn Amado J Zurita Sumit K Subudhi Jianhua Zhang Wenyi Wang Chad D Huff Patricia Troncoso James P Allison Padmanee Sharma Christopher L Logothetis

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2024)

Adding ipilimumab to AAPA did not improve outcomes in men with androgen responsive mCRPC. Despite the addition of carboplatin+cabazitaxel, men in the Unsatisfactory group had shortened survivals. Adaptive designs can enrich for biologically and clinically relevant disease subgroups, to contribute to the development of marker-informed, risk-adapted therapy strategies in men with prostate cancer.

Keyphrases